Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | LTT462 |
Trade Name | |
Synonyms | LTT 462 |
Drug Descriptions |
LTT462 inhibits ERK, resulting in decreased downstream signaling, and reduced ERK-dependent proliferation and survival of tumor cells (NCI Drug Dictionary). |
DrugClasses | ERK Inhibitor (pan) 21 |
CAS Registry Number | NA |
NCIT ID | C126687 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Dabrafenib + IAG933 + LTT462 | Dabrafenib IAG933 LTT462 | 1 | 0 |
Dabrafenib + LTT462 | Dabrafenib LTT462 | 0 | 1 |
Dabrafenib + LTT462 + LXH 254 | Dabrafenib LTT462 LXH 254 | 0 | 1 |
Dabrafenib + LTT462 + Spartalizumab | Dabrafenib LTT462 Spartalizumab | 0 | 1 |
Dabrafenib + LTT462 + TNO155 | Dabrafenib LTT462 TNO155 | 0 | 1 |
Dabrafenib + LTT462 + Trametinib | Dabrafenib LTT462 Trametinib | 0 | 1 |
LTT462 | LTT462 | 0 | 1 |
LTT462 + LXH 254 | LTT462 LXH 254 | 4 | 2 |